A B S T R A C T In vitro
have two distinct patterns of susceptibility to trimethoprim-sulfamethoxazole (TMP/SMZ); strains with low minimum inhibitory concentration and high minimum bactericidal concentration (tolerant) and those with both low minimum inhibitory concentration and minimum bactericidal concentration (kill-sensitive). Tolerant H. influenzae strains were found to elaborate significantly more type b capsular polysaccharide, a linear polymer of ribosyl ribose phosphate (PRP), than kill-sensitive strains. Tolerant strains became susceptible to killing by TMP/SMZ when type b capsule was physically removed, but reacquired tolerance following growth and reversion to original (mucoid) phenotype. Susceptibility of wild (type a, b, c), isogenic (type b and untypable), and transformed (type b and d) strains indicated that elaboration of type b capsule was associated with TMP/SMZ tolerance.
In a second series of studies, virulence of H. influenzae in the infant rat model was correlated with in vitro tolerance. Tolerant strains (13/13) caused systemic disease while none (0/7) of kill-sensitive strains were pathogenic. The efficacy of TMP/SMZ in the treatment of invasive infection was evaluated in rats with established bacteremia and meningitis. TMP/ SMZ failed to eradicate H. influenzae b from the blood in 85% (17/20) or from the cerebrospinal fluid in 95% (19/20) of infected animals. Thus, in vitro tolerance correlated with therapeutic failure in vivo. INTRODUCTION Haemophilus influenzae type b (Hib)' is a major pathogen of infancy and childhood resulting in bloodstream infections associated with serious complications such as meningitis. In recent years, attention has been focused on the occurrence of secondary cases of invasive Hib infections in households or day-care centers where susceptible young children are in intimate contact and at high risk of developing invasive disease (1) (2) (3) (4) (5) . Efforts to interrupt person-to-person spread of Hib in these settings have included the use of antibiotics such as trimethoprim-sulfamethoxazole (TMP/ SMZ) (1, 3, 7) , rifampin, (6) (7) (8) , cefaclor (9, 10) , and ampicillin (11) (12) (13) . During an outbreak of Hib carriage and disease in a chronic disease hospital (3), TMP/ SMZ failed to eradicate nasopharyngeal carriage in 30% of carriers, although the minimal inhibitory concentration (MIC) of TMP/SMZ for these H. influenzae (Hi) strains indicated that they were susceptible. Subsequent investigations by Kirven and Thornsberry (14) showed that although some strains of Hi were killed by low concentrations of TMP/SMZ (<0.03:0.6 ,ug/ ml), a proportion of strains, hereafter designated tolerant, were inhibited but not killed by concentrations of TMP/SMZ as high as 4:76 ug/ml. The distinction seemed pertinent, since all Hi strains that persisted in the nasopharynx of TMP/SMZ-treated children were tolerant (14) . (10 ml) and grown at 380C until late stationary phase (-12 h). After centrifugation at 5,000 g for 15 min 0.1 ml of cell-free supernatant was assayed for PRP. A standard curve was obtained using known concentrations of purified PRP.
Susceptibility to TMP/SMZ. A modification of the broth dilution test reported by Kirven Mueller-Hinton broth (low in thymidine) was supplemented to contain 5% filtered horse blood and 2.5 sg/ml NAD. Stock solutions of TMP and SMZ (obtained from Hoffman-LaRoche, Inc., Nutley, N. J.) were freshly prepared in the appropriate diluents. Further dilutions were made with the supplemented Mueller-Hinton broth. TMP was tested in concentrations ranging from 0.004 to 8 ,g/ml, SMZ from 0.15 to 152 ,g/ml and TMP/SMZ from 0.004:0.08 to 4:76 gg/ml.
From an overnight growth of Hi on a chocolate plate, three colonies were inoculated into 5 ml supplemented MuellerHinton broth. The tube was shaken for 4 h at 37°. Appropriate dilutions of the cultured bacterial suspension were made to achieve a final concentration of 104 bacteria/ml. 1 ml of this diluted bacterial suspension was inoculated into 1 ml of the antibiotic dilution (final volume 2 ml). The tubes were incubated for 18 h at 350 in 5% CO2. The MIC was read as the lowest concentration of drug inhibiting visible growth of Hi. To determine the minimal bactericidal concentration (MBC), 0.01 ml from each tube was transferred to a chocolate plate and incubated at 350 in 5% CO2 for 24 h. The MBC was read as the lowest concentration of the drug which prevented growth. A tolerant strain was defined as a strain which was inhibited but not killed by concentrations of TMP/SMZ as high as 4:76 ,g/ml. Strains were also examined for tolerance to other antibiotics including tetracycline, chloramphenicol, rifampin, cefamandole, and ampicillin.
In one series of experiments, the MBC of TMP/SMZ for three tolerant strains (401, Bloch, Eag) and one kill-sensitive strain (S) was measured before and after removal of surface PRP. PRP was removed by suspending 109 bacteria in 10 ml of cold, buffered saline (pH 7.0) and shaking vigorously for 5 min by hand. After shaking, an aliquot of the bacterial suspension was centrifuged at 4,000 g at 40 for 10 (Fig. 1) .
To investigate directly the relationship between elaboration of PRP and tolerance to TMP/SMZ, strain 401 was suspended in neutral buffered saline and shaken to remove surface PRP. Successive washes increased the susceptibility of the bacteria to killing by TMP/SMZ (Fig. 2) (Fig. 3) . Growth of Sb was inhibited whereas more than 99% of strain S were killed. At 3 h Gram-stained smears of both S and Sb organisms organisms were seen; at 18 h many of the Sb organisms appeared filamentous (Fig. 4) .
Because these findings demonstrated a direct relationship between elaboration of PRP and in vitro tolerance to TMP/SMZ, we hypothesized that PRP was limiting the entry of either TMP or SMZ (or both) into the bacterial cell. However, TMP and SMZ, alone or in combination, inhibited both kill-sensitive and tolerant strains at similar concentrations (Table II) . Thus PRP did not prevent TMP or SMZ from entering the bacteria to inhibit replication.
We examined the TMP/SMZ susceptibility of different serotypes elaborating copious amounts of capsule as judged by colonial appearance. Wild types a (strain Morg) and c (strain ATCC No. 9007) were inhibited by .0.03:0.6 ;ig/ml and killed by .0.12:2.4 ,ug/ml TMP/SMZ, respectively. (Table III) . 20 rats were randomly assigned to the treatment group and 5 served as controls. No significant difference (P > 0.1) in the mean numbers of bacteria in blood or CSF was observed between treatment and control groups. 6 h after treatment none of the rats receiving saline (control group) has sterile blood or CSF cultures. In contrast, 13 cultures (P < 0.001), while a 10-fold reduction in the number of bacteria in blood (from 3.9±0.6 X 104/ml to 1.5±0.6 X 103/ml) was seen in the remaining 7 animals. CSF cultures in 7 of 20 treated animals were negative (P < 0.05); a 10-fold reduction (from 5.6±0.8 X 104 to 3.6±0.7 X 103/ml) was found in the 13 rats whose CSF cultures remained positive. There was no change in the mean blood or CSF bacterial counts of controls. Cultures were repeated 54 h after cessation of TMP/SMZ treatment. Of the 13 blood and seven CSF cultures negative after 6 h of treatment, 10/13 blood (77%) and 6/7 CSF specimens (86%) had reverted to positive. The mean bacterial counts for blood (6.3±1.6 X 103/ml) and CSF (3.9±0.6 X 104/ml) were similar to those of untreated controls (8.3±2.2 X 103 and 4.8±0.9 X 104/ml, respectively). Thus, despite an initial apparently favorable therapeutic response, TMP/SMZ in the dosages used did not eradicate infection. (Higher dosages of TMP/SMZ caused chemical peritonitis and animal mortality preventing evaluation of higher doses of medication.) These findings indicated that TMP/SMZ tolerance in vitro correlated with therapeutic failure in vivo. DISCUSSION Previous studies showed that 0.03/0.6 ,ug/ml concentrations of TMP/SMZ inhibited virtually all strains of Hi. However, the majority ('60%) of type b strains are not killed by concentrations of TMP/SMZ exceeding 4/76 lAg/ml (14) . This in vitro tolerance to TMP/ SMZ has an important clinical correlate; tolerant Hi persist in the nasopharynx of children after they have been treated with oral TMP/SMZ. The present studies show that tolerance to TMP/SMZ is associated with elaboration of PRP-the type b capsular polysaccharide and a major virulence determinant of Hi. This is exemplified by the fact that all 13 tolerant strains but none of the kill-sensitive strains produced bacteremia and meningitis in infant rats. In addition, the incidence and magnitude of bacteremia were significantly greater with KW-20 b organisms than with KW-20 d organisms. No detectable bacteremia occurred with the noncapsulated strain KW-20 (18) . These observations have implications concerning the use of TMP/ SMZ in the prevention and treatment of Hi infections. In addition to the ineffectiveness of TMP/SMZ in eradicating nasopharingeal carriage of Hib (3) our studies in an animal model showed that TMP/SMZ treatment failed to eradicate Hib from either blood or CSF. Concentrations of TMP and SMZ in blood and CSF of the rat were similar to those recommended in treating systemic infections in humans (27) particularly if susceptibility testing shows the infecting strain to be tolerant to TMP/SMZ in vitro.
In describing some strains of Hi as tolerant to TMP/ SMZ it should be noted that the term was first coined by Tomasz and his colleagues to describe the unique response of lysis-defective pneumococci to penicillin (28) . These insightful investigations showed that f,-lactam antibiotics result in inhibition of pneumococci (also streptococci and staphylococci) by mechanisms that are distinct from those resulting in killing and lysis. By analogy, it seems that the mediators and/or target sites for the inhibition of Hi by TMP/SMZ may be distinct from those that determine killing or lysis.
Inhibition of Hi by TMP and SMZ occurs through its action on the enzymes dihydrofolate reductase and dihydropteroate synthetase, respectively. This action limits the availability of folates required as coenzymes in the biosynthesis of nucleic acids; ultimately, DNA synthesis and bacterial cell division ceases. It is also well documented that TMP/SMZ may be bactericidal to Hi in vitro, although the mechanism of killing or lysis is not well understood and the in vitro conditions necessary for demonstrating the lethal action of TMP/ SMZ are critical. It has been suggested that death is due to the abnormal growth which occurs when Hi are deprived of thymidine-conditions which permit continued synthesis of protein. Bushby et al. (29) have drawn attention to the morphologic changes occurring in Hi exposed to TMP/SMZ; the bacteria evolve into long, broad, filamentous forms. It was proposed that these abnormalities in structure were consistent with lethal action of the antibiotic caused by thymineless death. In our studies, isogenic, capsulated (strain Sb) and relatively capsule-deficient (strain S) Hi behaved very differently when exposed to identical concentrations of TMP/SMZ (Fig. 3 ). 6 h after exposure to TMP/ SMZ the majority of strain S had undergone lysis (no bacteria visible on stained smears). In contrast, strain Sb did not undergo lysis although TMP/SMZ was bacteriostatic. Importantly, after 18 h of exposure to the antibiotic, inoculation of a washed suspension of the morphologically altered TMP/SMZ-exposed Sb organ-664 R. Yogev and E. R. Moxon isms into rats showed that they were viable and virulent. These observations suggest that the morphologic changes may not necessarily be related to thymine deprivation as suggested by Bushby. A further important question is why Hi that elaborate PRP do not lyse when exposed to high concentrations of TMP/SMZ, whereas PRP-deficient strains or strains elaborating heterologous capsules do. The comparison of the type b and type d transformants of KW-20 would seem particularly striking in this regard since these strains would possess near homology of DNA other than in those regions specifying elaboration of capsular polysaccharide (29) ; outer membrane proteins of these strains were found to be identical.2 Taken together, our observations using a variety of transformants suggest that elaboration of PRP is related to both TMP/ SMZ tolerance and virulence for rats (18) . It seems unlikely that tolerance of Hi to TMP/SMZ can be explained by proposing that elaboration of PRP physically impedes the entry of TMP or SMZ into the bacterium. The MIC for either TMP or SMZ alone was not substantially different for tolerant as compared to kill-sensitive strains. Rather, the mechanisms of inhibition and killing or lysis may be determined by distinct mechanisms. A reasonable possibility is that elaboration of PRP influences the structural integrity of the bacterial cell so as to render it less susceptible to killing.
In summary, routine antibiotic susceptibility testing of clinical bacterial isolates has traditionally relied predominantly upon assaying the MIC of bacteria. However, the recognition of tolerance is of substantial importance to the clinician because selection of successful therapy for particular bacteria (e.g., Staphylococcus aureus) or of specific infections (e.g., endocarditis) may be critically dependent upon the MBC. The present studies demonstrate a novel example of tolerance in Hi in which a major determinant of its pathogenicity (the type b capsule) promotes enhanced resistance to antibiotic killing in association with ther-apeutic failure in vivo. Further studies may shed light not only upon the mechanisms by which tolerant strains of Hi resist the lethal action of TMP/SMZ, but may also provide insights into the biochemical basis of virulence in Hi.
